{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "RBD",
      "SARS-CoV-2",
      "kinetic",
      "serology",
      "spike protein",
      "vaccine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "36493367",
  "DateCompleted": {
    "Year": "2023",
    "Month": "07",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "07",
    "Day": "06"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1093/labmed/lmac127"
    ],
    "Journal": {
      "ISSN": "1943-7730",
      "JournalIssue": {
        "Volume": "54",
        "Issue": "4",
        "PubDate": {
          "Year": "2023",
          "Month": "Jul",
          "Day": "05"
        }
      },
      "Title": "Laboratory medicine",
      "ISOAbbreviation": "Lab Med"
    },
    "ArticleTitle": "Long-Term Dynamic of Anti-TrimericS and Anti-RBD Antibodies in Naive and COVID-19 Recovered mRNA-1273 Vaccine Recipients.",
    "Pagination": {
      "StartPage": "388",
      "EndPage": "391",
      "MedlinePgn": "388-391"
    },
    "Abstract": {
      "AbstractText": [
        "Patients and physicians are increasingly requesting their clinical laboratory to provide SARS-CoV-2 serology interpretation. Our study aimed to assess the evolution of SARS-CoV-2 antibodies in Moderna-vaccinated health care workers.",
        "We analyzed the evolution of mRNA-1273 (Moderna)-elicited antibodies by 2 high-throughput assays, TrimericS IgG (Diasorin) and SARS-CoV-2 IgG-II (Abbott).",
        "After the first injection, the COVID-19-recovered vaccinees showed a serological response as strong as that observed 1\u00a0month after the second injection in participants without COVID-19 history. Although remaining above the positivity thresholds, the TrimericS immunoglobulin G (IgG) and anti-RBD (receptor-binding domain) IgG levels fell considerably between 1 and 7 months postvaccination, dropping to 10.6% and 13% for the COVID-19 recovered subgroup and to 11.7% and 9.3% for the COVID-19 naive subgroup.",
        "Regardless of the test used, a decrease in circulating anti-SARS-CoV-2 IgG levels should be expected a few months after vaccination. As this decline does not preclude the efficacy of immune response, caution is necessary when interpretating postvaccination serological data."
      ],
      "CopyrightInformation": "\u00a9 The Author(s) 2022. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine, Centre Hospitalier Universitaire (CHU) de Tivoli, La Louvi\u00e8re,Belgium."
          }
        ],
        "LastName": "Ocmant",
        "ForeName": "Annick",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine, Centre Hospitalier Universitaire (CHU) de Tivoli, La Louvi\u00e8re,Belgium."
          }
        ],
        "LastName": "Roisin",
        "ForeName": "Sandrine",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases, Centre Hospitalier Universitaire (CHU) de Tivoli, La Louvi\u00e8reBelgium."
          }
        ],
        "LastName": "Mathieu",
        "ForeName": "Delphine",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Laboratory Medicine, Centre Hospitalier Universitaire (CHU) de Tivoli, La Louvi\u00e8re,Belgium."
          }
        ],
        "LastName": "Brauner",
        "ForeName": "Jonathan",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Internal Medicine, Centre Hospitalier Universitaire (CHU) de Tivoli, La Louvi\u00e8reBelgium."
          }
        ],
        "LastName": "De Leener",
        "ForeName": "Fr\u00e9d\u00e9ric",
        "Initials": "F"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Lab Med",
    "NlmUniqueID": "0250641",
    "ISSNLinking": "0007-5027"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "EPK39PL4R4",
      "NameOfSubstance": "2019-nCoV Vaccine mRNA-1273"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Immunoglobulin G"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "2019-nCoV Vaccine mRNA-1273"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [
        "diagnosis",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunoglobulin G"
    }
  ]
}